The clinical significance of atrial fibrillation in non-high risk Brugada syndrome - The BruFib Study

29 August 2025 (07:00 - 18:00)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Esther Scheirlynck

Cardiocentro Ticino Institute, Lugano (Switzerland)

5 More presentations in this session

Presentation thumbnail

1-year follow-up in patients identified with possible atrial fibrillation: sub-analysis of the omron heart study

Doctor Y. Kakei (Kyoto, JP)

Abstract Slides Video

Presentation thumbnail

AI-tools to make smartwatch ECG incrementally closer to clinical application

Professor L. Mainardi (Milan, IT)

Abstract Slides Video

Presentation thumbnail

Fully digital enrollment in the NORwegian atrial fibrillation self-SCREENing trial (NORSCREEN)

Mr M. Boskovic (Oslo, NO)

Abstract Slides Video

Presentation thumbnail

Hypokalemia as a trigger for atrial fibrillation: Insights from patients with implantable loop recorders

Mr A. Krebs Hessellund (Copenhagen, DK)

Abstract Slides Video

Presentation thumbnail

Atrial fibrillation screening effects according to genetic risk: a secondary analysis of the randomized LOOP study

Mr O. Vad (Copenhagen, DK)

Abstract Slides Video

Access the full session

Session thumbnail

New insights from atrial fibrillation monitoring and screening

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025

You may be interested in

Congress Presentation

Predicting atrial fibrillation from ECG characteristics

Congress Presentation

Implantable cardioverter-defibrillator implantation in incidental Brugada Syndrome diagnosed after treatment with sodium channel-blocker

Congress Presentation

Prognostic implications of atrial fibrillation in young patients without overt heart disease - an early marker of future cardiomyopathy ?

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources